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INTRODUCTION
“When you solve one difficulty, other new difficulties arise. You then 
try to solve them. You can never solve all difficulties at once”
- P.A.M.CHIRAC
It is this spirit of learning more about how echocardiography can be 
used  to  evaluate  Right  ventricle  function  in  pulmonary  hypertension 
patients, which helps us. With multivarious etiologies causing pulmonary 
hypertension,  making  an  accurate  diagnosis,  evaluating  for  the  cause, 
monitoring the disease course and detecting complications of the disease 
has always been a challenge. Selecting the most appropriate for screening, 
diagnosing and monitoring the disease has been a subject of controversy. 
Although there is no consistent  and large data available in India 
revealing the exact incidence and prevalence of the disease, the increase 
in disease burden is certainly palpable and will continue to increase with 
time.  With  high  mortality  rates  if  left  untreated  and  with  very  little 
treatment  options  in  our  hands,  it  definitely  poses  a  challenge  to  the 
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medical  fraternity  for  an  early  diagnosis  and  intervention  before 
complications  intervene.  Most  common  cause  of  death  in  pulmonary 
hypertension  is  right  ventricular  failure.  Unfortunately  most  patients 
present to us too late for any kind of meaningful intervention. 
So as physicians, it is important for us to play a critical role in the 
evaluation of the use of  appropriate diagnostic  procedures and therapy 
modalities in the early detection and treatment of this disease. Rigorous 
and  expert  analogues  of  the  available  data  that  document  the  relative 
benefits and risks of the procedures can produce helpful guidelines that 
improve  the  effectiveness  of  care  optimize  patient  outcomes  and 
favourably  affect the overall cost of care through a focus of resources on 
the most effective strategies.
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REVIEW OF LITERATURE
BACKGROUND
Pulmonary Hypertension is a distinct  clinical entity characterised 
by  sustained  elevation  in  Pulmonary  artery  pressure  leading  to  right 
ventricular failure and death. Abnormalities in right ventricular function 
are known to occur in patients with pulmonary arterial hypertension and 
be detected at an early stage by Doppler echocardiography1.
There is not much of data available from studies conducted in India 
regarding utility of Echocardiography in studying Right ventricle function 
in Pulmonary Hypertension patients.  Right ventricle (RV) dysfunction is 
an  important  element  in  determining  prognosis  in  Pulmonary 
Hypertension patients. Identification of early RV dysfunction is of utmost 
clinical  importance  because  two-thirds  of  the  deaths  in  Pulmonary 
Hypertension (PH) patients are attributable to RV failure2,3.  The essential 
noninvasive  test  in  the  screening  and  evaluation  of  Pulmonary 
Hypertension (PH) is Doppler echocardiography. Echocardiography can 
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help not only to estimate right ventricular function, but also exclude the 
presence  of  left-heart  disease.  Doppler  assessments  can  be  used  to 
estimate the right ventricular systolic pressure (RVSP) and to evaluate for 
the presence of intracardiac shunts and other forms of congenital heart 
disease  4,5.  Studies by Tei et al. have confirmed the close correlation of 
echocardiographically estimated pulmonary arterial pressure and Doppler 
derived right ventricle indices like Myocardial performance Index, with 
invasive measurements in patients with pulmonary hypertension 6,7,8.9. 
A  thorough  understanding  of  the  pertinent  facts  regarding 
pulmonary hypertension is absolutely necessary before treading into its 
complexities in treatment and management. The changing concepts about 
pulmonary hypertension mandate the review of the current literature of 
pulmonary hypertension.
Recently,  parameters  for  normal  pulmonary  arterial  systolic 
pressure  derived  by  echo  Doppler  studies  have  been  published  which 
suggest  that  the  upper  limit  of  normal  of  pulmonary  arterial  systolic 
pressure  in  the  general  population  may  be  higher  than  previously 
appreciated  10.  Importantly,  however,  the  study  characterized  changes 
based on age and found a modest increase in pulmonary arterial pressure 
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with age similar to what exists in the systemic circulation.
DEMOGRAPHICS
Data  regarding  the  prognostic  implications  of  demographic 
variables such as age, gender, and time of onset of symptoms to diagnosis 
are inconsistent. The National Institute of health (NIH) Registry was the 
first large-scale evaluation of prognostic factors in Idiopathic pulmonary 
hypertension (IPAH). Age, time from onset of symptoms to diagnosis, and 
gender were not predictive of survival. In a retrospective, single center, 
uncontrolled case series of 61 patients with IPAH from India, younger age 
was associated  with  a  worse  prognosis.  It  should  be  noted  that  this 
population was younger than that included in the NIH Registry (mean age, 
24.6 ± 11.8 years as compared to 36 ± 15 years [± SD]). In a study that 
included patients with many etiologies of  PAH who were treated with 
epoprostenol, older age at diagnosis indicated a worse prognosis for those 
above the median. This, however, may be confounded by the inclusion of 
patients with the scleroderma spectrum of disease who tend to be older 
and also had a worse prognosis. A national survey of IPAH was conducted 
in Israel and identified 44 patients with a mean age of 43 ± 13 years (± 
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SD). Although they did not find age to be a prognostic variable, longer 
time of onset from symptoms to diagnosis was associated with a worse 
prognosis.
DEFINITION OF PULMONARY HYPERTENSION
Pulmonary arterial hypertension is defined as a sustained elevation 
of pulmonary arterial systolic pressure to more than 25 mm Hg at rest or 
to more than 30 mm Hg with exercise, with a mean pulmonary-capillary 
wedge pressure and left ventricular end-diastolic pressure of less than 15 
mm Hg 11. 
The  pressure  within  the  pulmonary  arterial  system  may  be 
increased for one of two reasons – increased flow or increased resistance 
within the pulmonary circulation, both of which lead to progressive and 
irreversible changes in the pulmonary vascular bed to result  in chronic 
pulmonary hypertension. 
PATHOLOGY OF PULMONARY HYPERTENSION 12,13
Pulmonary  endothelial  cell  and/or  vascular  smooth  muscle 
dysfunction is the probable underlying basis for most forms of pulmonary 
hypertension.  Morphological  abnormalities  in  each  cell  line  of  the 
pulmonary  vasculature  have  been  described  in  cases  of  IPAH.  The 
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endothelium in particular displays marked heterogeneity in the pulmonary 
vascular bed. Vascular alterations in  pulmonary hypertension  involve the 
entire arterial tree (Fig-1)  and include: 
1. Main  elastic  arteries, atheromas  similar  to  those  in  systemic 
atherosclerosis; 
2. Medium-sized  muscular  arteries, proliferation  of  myointimal 
cells and smooth muscle cells, causing thickening of the intima and 
media with narrowing of the lumina; and 
3. Smaller arteries and arterioles, thickening, medial hypertrophy, 
and reduplication of the internal and external elastic membranes
 Smooth muscle cell hypertrophy and increased connective tissue 
and  extracellular  matrix  are  found  in  the  large  muscular  and  elastic 
arteries. In the subendothelial layer, increased thickness may be the result 
of recruitment and/or proliferation of smooth muscle–like cells. Various 
growth factors are involved in the smooth muscle hypertrophy. (Fig -2) 
They  are1.Prostaglandins  2.Nitric  Oxide  3.Endothelin  4.Serotinin 
5.Angiotensin II. These stimulatory signals by different pathways trigger 
the smooth muscle hypertrophy. 
There  are  three  significant  pathways  which  are  involved  in  the 
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pathogenesis of PAH14 (Fig-3). They are
1. ENDOTHELIN Pathway
2. NITRIC OXIDE Pathway 
3. PROSTACYCLIN Pathway.
ENDOTHELIN Pathway15
       Endothelin (ET) is a potent mitogenic and vasoconstrictor peptide 
that also plays a role in the regulation of pulmonary vascular tone. ET-1 is 
the  predominant  isoform  of  endothelin  in  the  cardiovascular  system, 
generated through the cleavage of pre-pro ET-1 to big ET-1 and then to 
ET-1. ET-1 biosynthesis is regulated by physiochemical factors such as 
blood  flow,  pulsatile  stretch,  hypoxia,  and  thrombin.  Endogenous 
inhibitors of ET-1 synthesis include nitric oxide and prostacyclin. ET-1 
exerts  its  major  vascular  effects  through  activation  of  two  distinct  G 
protein–coupled  ETA and  ETB receptors.  ETA receptors  induce 
vasoconstriction  and  cellular  proliferation  by  increasing  intracellular 
calcium.  ETB receptors  are  localized  on  endothelial  cells  and to  some 
extent on smooth muscle cells and macrophages. The activation of ETB 
receptors  stimulates  the  release  of  nitric  oxide  and  prostacyclin  and 
prevents apoptosis.
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NITRIC OXIDE Pathway16
Endothelial NO synthase is found in the vascular endothelium of 
the  normal  pulmonary  vasculature.  It  generates  nitric  oxide  from  the 
vascular endothelium in response to shear stress, bradykinin and thrombin 
from L-arginine which is present in endothelium. No inhibits the growth 
of  vascular  smooth  muscle  cells  by  increasing  the  cGMP  levels. 
Endothelial dysfunction causes reduced endothelial  NO synthase which 
leads to smooth muscle hypertrophy.
PROSTACYCLIN Pathway17
Prostaglandins  I2 (PGI2)  and  E1 (PGE1)  are  active  pulmonary 
vasodilators,  whereas PGF2a and PGA2 are pulmonary vasoconstrictors. 
Prostacyclin functions through cell-surface G protein–coupled receptors 
linked  to  different  signaling  pathways.  Prostacyclin  is  a  powerful 
vasodilator  and  inhibitor  of  platelet  aggregation  through  activation  of 
cyclic  adenosine  monophosphate  (cAMP).Prostacyclin  release  prevents 
smooth muscle proliferation.Impaired prostacyclin release causes cellular 
proliferation and vasoconstriction.
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An Apoptosis-Based Theory for the Development of PAH 18(Fig—4)
The central focus of this hypothesis is that apoptosis shows aspatio-
temporal  diversity  within  the  vascular  wall  as  PAH  develops.  An 
abnormality in the BMP[Bone Morphogenitic Protein] axis, inherited or 
acquired,  will  promote  the  apoptosis  of  Pulmonary  Artery  Endothelial 
Cells [PAEC], particularly in response to injury (viral infection, increased 
shear stress,etc). Initial PAEC death will cause loss of small capillaries 
(which are essentially PAEC tubes), increasing the flow and shear stress 
in  the  remaining  vessels,  amplifying  the  effect.  The  emergence  of 
apoptosis-resistant  PAECs  expressing   survivin  will  lead  to  the 
proliferation in the intima and in plexogenic lesions. At the same time loss 
of  PAECs would allow for  exposure of  PASMCs [Pulmonary  Smooth 
Muscle Cells] to circulating growth factors .Such factor, PDGF has been 
shown to induce the expression of survivin  in the vascular smooth muscle 
cells.  Survivin  itself  also  induces  the  production  of  PDGF  in  human 
vascular  smooth  muscle  cells.  This  positive  feedback  allows  for 
amplification of the survivin pathway and thus the resistance to apoptosis. 
In summary,  early  PAH is  characterized by increased apoptosis  in  the 
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endothelial  layer.  In  contrast,  late  PAH is  characterized by  suppressed 
apoptosis and increased proliferation in both the intima and the media.
ROLE OF SEROTININ 19,20.
          Elevated plasma levels of serotonin and reduced platelet serotonin 
concentration have been described in IPAH patients. The abnormality in 
platelet serotonin handling is a primary process in the evolution of their 
pulmonary  hypertension.  Mutations  in  the  serotonin transporter  and 5-
hydroxytryptamine  2B  (5-HT2B)  receptor  have  now  been  reported  in 
patients with IPAH.
GENETICS OF PAH 21 (Fig—5)
Bone Morphogenetic Protein Receptor Type 2 Gene is an important 
gene in the mediating the PAH.Mutations in BMPR-2 gene resulting in a 
predisposition to proliferation small pulmonary arteries. TGF-b pathway 
mediated  through  BMPR-2 is  critical  for  the  maintenance  and  normal 
response to injury of the pulmonary vasculature.
5-HTT expression is elevated in cultured pulmonary artery smooth 
muscle  cells  from  patients  with  PAH  and  that  proliferation  was  also 
increased and related to 5-HTT expression and 5-HTT activity. 5-HTT is 
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encoded by a single gene on chromosome 17q11.2, 
CLASSIFICATION  AND  STAGING  OF  PULMONARY 
HYPERTENSION
Pulmonary  hypertension  can  occur  from  diverse  etiologies  and 
number of attempts has been made to classify the disease. The original 
classification,  established  at  a  World  Health  Organization  (WHO) 
symposium in 1973, classified pulmonary hypertension into groups based 
on  the  known  cause,  i.e.  secondary  and  defined  primary  pulmonary 
hypertension (PPH) as a separate entity of unknown cause. PPH was then 
classified into three histopathological patterns: 
 (a) Plexogenic arteriopathy           (b) Recurrent thromboembolism and 
 (c) Venoocclusive disease. 
In  1998,  a  new  classification  for  pulmonary  hypertension  was 
developed  that  focused  on  the  biologic  expression  of  the  disease  and 
etiologic factors  in an attempt to group these illnesses on the basis  of 
clinical  similarities.  This  classification  serves  as  a  useful  guide  to  the 
clinician  in  organizing  the  evaluation  of  a  patient  with  pulmonary 
hypertension and developing a treatment plan.
In  2003  the  Third  World  Symposium updated  the  classification 
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system,  notably  dropping  the  term  "primary"  altogether.  They  also 
stressed  that  the  staging  of  patients  with  PH should  be  based  on  the 
functional capacity of the patient rather than on hemodynamic parameters. 
The World Health Organization classification system, a modified form of 
the  New York  Heart  Association  functional  classification  system,  was 
recommended by the Symposium as the preferred staging system. The 
NYHA  functional  classification  (NYHA-FC)  has  been  of  prognostic 
importance to predict survival in PH.
Revised Clinical Classification of Pulmonary Hypertension22 (Venice 
2003)
Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH):
1.3.1. Collagen vascular disease
1.3.2. Congenital systemic-to-pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
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1.3.6.  Other  (thyroid  disorders,  glycogen  storage  disease, 
Gaucher  disease,  hereditary  hemorrhagic  telangiectasia, 
hemoglobinopathies,  myeloproliferative  disorders, 
splenectomy)
1.4 Associated with significant venous or capillary involvement
1.4.1 Pulmonary veno-occlusive disease (PVOD)
1.4.2 Pulmonary capillary hemangiomatosis (PCH)
2. Pulmonary hypertension with left heart disease
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
3.  Pulmonary  hypertension  associated  with  lung  disease  and/or 
hypoxemia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep-disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
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4.  Pulmonary  hypertension  due  to  chronic  thrombotic  and/or  embolic 
disease
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Non-thrombotic pulmonary embolism (tumor, parasites, 
       foreign material)
5. Miscellaneous:
Sarcoidosis,  histiocytosis-X,  lymphangiomatosis,  compression  of 
pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)
    The  functional  classification  patterned  after  the  New  York  Heart 
Association Functional Classification for heart disease was developed to 
allow comparisons of patients with respect to the clinical severity of the 
disease process. 
WHO  Functional  Classification  of  Pulmonary  Hypertension
Class  I –  Patients  with  pulmonary  hypertension  but  without  resulting 
limitation of physical activity. Ordinary physical activity does not cause 
undue dyspnea or fatigue, chest pain 
Class  II –  Patients  with  pulmonary  hypertension  resulting  in  slight 
limitation  of  physical  activity.  They  are  comfortable  at  rest.  Ordinary 
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physical  activity  causes  undue  dyspnea  or  fatigue,  chest  pain,  or  near 
syncope.
Class  III –  Patients  with  pulmonary  hypertension resulting  in  marked 
limitation of  physical  activity.  They are comfortable  at  rest.  Less than 
ordinary  activity  causes  undue dyspnea  or  fatigue,  chest  pain,  or  near 
syncope.
Class IV – Patients with pulmonary hypertension with inability to carry 
out any physical activity without symptoms. These patients manifest signs 
of right heart failure. Dyspnea and/or fatigue may be present even at rest. 
Discomfort is increased by any physical activity.
NYHA-Functional classification (NYHA-FC) has been included 
in several studies of patients with PAH, and has been used in two ways in 
these reports: as a variable that might be predictive of survival in patients 
with PAH, and as an outcome to assess the impact of therapies for PAH. 
Because  NYHA-FC  relies  on  patient  reporting  of  symptoms  as  an 
outcome, it may hold special importance for patients themselves, but it is 
also  useful  for  clinicians  trying  to  assess  prognosis  and  response  to 
therapy in patients with PAH. 
NYHA-FC has been associated with improved survival in several 
21
studies, but was found to be a significant predictor of mortality in only 
four studies. The NIH cohort study showed that among 194 patients who 
received a  diagnosis  showed that  the  risk  of  death  was  higher  among 
patients in NYHA-FC III or IV than among those in NYHA-FC I or II23. 
The median survival time among NYHA-FC I or II patients was nearly 6 
years, compared with 2.5 years for patients in NYHA-FC III and 6 months 
for patients in NYHA-FC IV. In a subsequent cohort study of 44 patients 
with IPAH, patients who were in NYHA-FC IV at the time of diagnosis 
had a significantly higher risk of death than patients in NYHA-FC I, II, or 
III. In another retrospective study of 51 patients with IPAH, patients in 
NYHA-FC III or IV had a shorter survival time than patients in NYHA-
FC II. A third study of 91 patients with PAH, demonstrated that patients 
who  were  in  NYHA-FC IV  (compared  with  NYHA-FC I,  II,  and  III 
patients combined) had a significantly decreased survival. In summary, 
higher NYHA-FC (III or IV) is associated with increased mortality both 
in treated and untreated patients with IPAH; in those receiving therapy, 
failure to improve NYHA-FC or deterioration in NYHA-FC, in and of 
itself, may be predictive of poor survival.
The initial evaluation of patients with PH should consist of testing 
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to  confirm  the  diagnosis,  a  search  for  causative  disorders  and 
complications from the disease, and a determination of the severity of the 
disease.
EVALUATION  OF  A  PATIENT  WITH  SUSPECTED  PULMONARY 
HYPERTENSION
Essential Evaluation Contingent Evaluation
History and physical examination Transesophageal echo (TEE)
Chest x-ray (CXR) Echo with bubble study
Electrocardiogram (ECG) CT chest ± high resolution
Pulmonary function testing(PFT) Pulmonary angiogram
Ventilation-perfusion scan (V/Q) Arterial blood gas
Transthoracic echo (TTE) Cardiac MRI
Blood tests: HIV, TFTs, LFTs, ANA Blood tests: Uric acid, BNP
Six-minute walk test (6MWD) Polysomnography
Overnight oximetry Cardiopulmonary exercise
Right heart catheterization (RHC) Open lung biopsy
Left-heart  disease,  valvular  heart  disease,  and  parenchymal  lung 
disease deserve special attention during this initial period of evaluation as 
they  are  common causes  of  pulmonary  arterial  pressure  elevation  and 
right ventricular failure.
A detailed history should be taken from the patient in an attempt to 
define  the  severity,  duration,  and  degree  of  acceleration  in  symptom 
severity.  The  patient  should  also  be  questioned  about  drugs  of  abuse, 
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herbal  medicines  and  supplements,  and  prescription  drugs  including 
appetite suppressants and anorexigens.
 
CLINICAL FEATURES
Patients  with  PH  usually  present  with  nonspecific  symptoms 
including dyspnea (60%), chest pain (40%), and fatigue. Symptoms are 
typically  related  to  inability  to  increase  cardiac  output  sufficiently  in 
response to  exertion and suboptimal  oxygen transport24.   The  onset  of 
right ventricular failure, manifest by a reduction in cardiac output and/or 
elevation  in  right  atrial  pressure,  is  usually  associated  with  a  marked 
clinical  deterioration  and  poor  prognosis.  The  rapidity  in  which  this 
occurs  in  highly  variable  and is  often  related  to  the  age of  onset  and 
associated conditions. Thus, patients with pulmonary arterial hypertension 
associated with congenital heart defects will more commonly have a slow, 
insidious onset of symptoms and develop right heart failure after decades, 
whereas patients with the CREST syndrome present later in life with a 
progressive downhill course. 
Studies  by  Harjai  et  al.  in  2002  indicate  that  right  ventricle 
dysfunction  in  pulmonary  hypertension  occurs  much  before  clinical 
examination  can  detect  or  ECG  evidence  of  right  heart  abnormality 
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surfaces.  Such  class  of  patients  are  the  ideal  candidates  for  Doppler 
echocardiography screening for RV dssynchrony. 
History  and  physical  examination  should  focus  on  signs  and 
symptoms  compatible  with  an  underlying  disease  including  collagen 
vascular diseases, liver disease, sleep apnea, thromboembolic disease, and 
abnormalities in thyroid function.
The  cardiac  examination  may  reveal  signs  such  as  an  increased 
pulmonic component of the second heart sound, an early systolic ejection 
click,  a  right  ventricular  fourth  heart  sound,  a  right  ventricular  heave, 
elevation  of  the  jugular  venous  pulsations,  or  a  murmur  of  either 
pulmonic or tricuspid insufficiency; however, none of these findings is 
specific to PH.
 In addition to undergoing a careful cardiac examination, the patient 
should be questioned about congenital heart disease and previous catheter 
ablation therapy for atrial fibrillation, a procedure that has been associated 
with pulmonary vein stenosis and PH.
ELECTROCARDIOGRAM
The  electrocardiogram  (ECG)  may  be  suggestive  of  right 
ventricular hypertrophy or right atrial enlargement and may demonstrate a 
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right  axis  deviation.  The  sensitivity  and  specificity  of  the  ECG  for 
detecting PH are sufficiently poor to preclude its use as a screening tool; 
however, patients with newly diagnosed PH should have at least 1 ECG to 
establish a baseline for future comparison.
In  a  study  of  51  patients  with  untreated  IPAH,  several  ECG 
variables, including increased P-wave amplitude in lead II, qR pattern in 
lead V1, and World Health Organization criteria for RV hypertrophy were 
associated with an increased risk of death25. The prognostic value of these 
factors remained even after controlling for PVR.
Although  all  patients  with  pulmonary  hypertension  had 
echocardiographic evidence of right ventricle dyssynchrony, there was no 
change in the QRS complex duration.
CHEST X RAY
Right  ventricular  or  pulmonary  artery  enlargement  may  be 
demonstrated  on  chest  x-ray.  Chest  x-ray  typically  shows  central 
enlargement of  the pulmonary arteries  with peripheral  "pruning."  Lupi 
and colleagues have described an index of PH based on the ratio of the 
summed horizontal measurements of the pulmonary arteries from midline 
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to  their  first  divisions,  divided  by  the  transverse  diameter.  Chest 
radiography  can  be  extremely  helpful  in  identification  of  coexisting 
conditions  such as  COPD,  kyphoscoliosis,  and interstitial  lung disease 
that may be responsible for the PH. 
COMPUTERISED TOMOGRAPHY OF THE CHEST
In  most  cases,  a  CT scan of  the chest  with  high-resolution cuts 
should be performed to evaluate for  the presence of parenchymal lung 
disease  and  mediastinal  disorders  that  could  cause  obstruction  of  the 
pulmonary vessels.
LUNG SCINTIGRAPHY
A ventilation-perfusion (V/Q) scan should be performed to evaluate 
for chronic thromboembolic disease. Prior studies have shown that V/Q 
scans have a high sensitivity and specificity for distinguishing between 
IPAH and chronic thromboembolic PH. Patients with a normal V/Q scan 
likely need no further evaluation for thromboembolic disease, but the poor 
correlation  between  the  findings  on  V/Q scanning  and  the  severity  of 
vascular obstruction demands that those patients with a positive scan be 
sent  for  pulmonary  angiography  to  accurately  define  the  degree  of 
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vascular  obstruction  and  to  identify  patients  who  would  benefit  from 
surgical thromboendarterectomy.
In addition to basic testing such as a complete blood count (CBC), 
an arterial blood gas (ABG), and a complete metabolic panel, the initial 
laboratory evaluation for patients with PH should include thyroid function 
tests, liver function tests (LFT), testing for collagen vascular diseases, and 
testing to detect the human immunodeficiency virus.
PULMONARY FUNCTION TEST26
All patients with PH should undergo baseline pulmonary function 
testing  including  spirometry,  determination  of  lung  volumes,  and 
evaluation  of  the  diffusion  limitation  for  carbon  monoxide  (DLCO). 
Pulmonary function testing may reveal evidence of significant obstructive 
or restrictive ventilatory defects that may be relevant to the etiology of 
PH.
SIX MINUTE WALK TEST26
Quantification  of  exercise  tolerance  is  often  performed  by 
measuring the distance that a patient can walk in 6 minutes (6MWD). The 
6MWD is  a  useful  tool  for  following patients  over  time  and,  for  this 
reason, serial determinations of the 6MWD distance should be made. The 
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6MWD has  been used  to  evaluate  patients  and has  been utilized as  a 
primary end point in recent clinical trials since earlier trials showed that 
6MWD was predictive of survival in patients with IPAH. Arterial oxygen 
desaturation > 10% during 6MWD has been shown to predict a 2.9 times 
increased risk of mortality over a median follow-up of 26 months.
PULSOXIMETRY
Screening for  unsuspected nocturnal  hypoxemia and sleep apnea 
should also be performed in those patients newly diagnosed with PH. No 
further testing is warranted if overnight oximetry on room air shows no 
desaturation.  Abnormal  oximetry  necessitates  a  full  polysomnogram to 
formally diagnose and determine the severity of sleep apnea, as nocturnal 
hypoxia may be an aggravating or even a causative factor for PH. 
Mechanisms  of  exercise  limitation  in  PH  include  arterial 
hypoxemia,  poor  cardiac  output  and  stroke  volume  in  response  to 
increased  demand,  lactic  acidosis  at  low  work  rates,  and  V/Q 
mismatching.  Cardiopulmonary  exercise  testing  provides  more 
physiologic information than the standard 6MWD; however, because it is 
technically  more  difficult,  is  time-consuming,  is  not  available  at  all 
centers, and may be less sensitive at detecting responses to treatment, it is 
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not routinely used. Patients with PAH typically show reduced peak VO2, 
reduced  peak  work  rate,  reduced  anaerobic  threshold,  reduced  peak 
oxygen  pulse,  increased  VE  and  VCO2 slope  indicating  inefficient 
ventilation, and reduced ratio of VO2 increase to work rate increase.
RIGHT HEART CATHETERISATION
Right  heart  Catheterisation  (RHC)  is  initially  performed  for  the 
purpose  of  diagnosing  PH;  other  important  information  can  also  be 
obtained from this test. The right atrial pressure, the mixed venous oxygen 
saturation,  the  cardiac  output  and  index,  and  the  pulmonary  vascular 
resistance all may be either measured or calculated during RHC27.  If a 
congenital  heart  defect  or  a  left-to-right  shunt  is  suspected,  one  may 
measure the oxygen saturation at several points throughout the course of 
the systemic venous system, right heart, and pulmonary arterial system 
looking for a step-up in saturation that would suggest the presence of a 
left-to-right  shunt.  Pressure  measurements  obtained  during  RHC  have 
been used to derive a prediction equation that  has been used to assess 
"predicted survival" and long-term effects of new treatments on survival. 
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The equation to predict survival based on the National Institutes of Health 
(NIH) registry data is:
P(t) = [H(t)]A(x,y,z); H(t) = [0.88 - 0.14t + 0.01t2]; A(x,y,z) = e(0.007325x + 0.0526y 
- .3275z)
where P(t) = a patient's chances of survival at 't' years; t = 1, 2, or 3 years; 
x = mean pulmonary artery pressure; y = mean right atrial pressure; and z 
= cardiac index.
If RHC confirms the diagnosis of PH, a vasodilator should be given 
to determine the degree of pulmonary arterial vasoreactivity, a factor that 
carries therapeutic and prognostic significance, as will be discussed later. 
No consensus exists regarding which agent should be used to perform this 
test;  however,  intravenous  epoprostenol,  intravenous  adenosine,  or 
inhaled nitric oxide is often chosen because all  of these are potent yet 
short-acting vasodilators. If the administration of a vasodilator causes the 
mean pulmonary arterial pressure to decrease ≥ 10 mmHg and reach ≤ 40 
mmHg, with an unchanged or increased cardiac output, the patient is said 
to  be  vasoresponsive.  The  main  reason  for  vasodilator  testing  is  to 
identify  patients  who are  likely  to  have  a  good long-term response  to 
treatment  with  calcium  channel  blockers  (CCBs)  alone.  Patients  with 
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IPAH are more likely to have a positive vasodilator response than those 
with  PAH associated  with  collagen  vascular  diseases.  Overall,  only  a 
minority  of  patients  (approximately  10% to 15%) are  likely  to  have  a 
positive vasodilator response.
MRI AND OPEN LUNG BIOPSY
The most recent recommendations from the ACCP did not advocate 
the routine use of magnetic resonance imaging (MRI) or open lung biopsy 
in the evaluation of patients with newly diagnosed PH. Cardiac MRI may 
provide additional  pressure estimates and estimates of  right  ventricular 
mass and volume; however, at present the incremental value of this tool 
over standard testing measures is not sufficiently high to recommend its 
use in all patients. 
Likewise, because of the risks associated with the procedure, The 
American College of Chest Physicians (ACCP) recommends lung biopsy 
“only if a specific question could be answered by tissue examination” in 
patients  with PH and its  “routine use to diagnose PH or determine its 
cause  is  discouraged.”  Such indications  could include  the  detection  of 
pulmonary  veno-occlusive  disease,  bronchiolitis,  active  vasculitis,  or 
pulmonary capillary hemangiomatosis.
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BIOMARKERS
Candidate serum biomarkers that have been studied to evaluate and 
assess prognosis  in  IPAH include atrial  naturetic  peptide (ANP),  brain 
naturetic peptide (BNP), catecholamines, and uric acid (UA). Nagaya and 
colleagues 28,29 studied 63 consecutive patients with Idiopathic Pulmonary 
Hypertension  (IPAH)  between  1994  and  1999.  Patients  with  IPAH 
underwent  blood  sampling  at  the time  of  baseline  catheterization  and 
subsequently treated with vasodilators.  Patients were followed up for a 
mean follow-up period of 24 months. Plasma ANP and BNP levels were 
low  in  control  subjects, and  both  were  increased  and  correlated  with 
functional class in patients with IPAH. ANP and BNP levels were also 
correlated with  mean  right  atrial  pressure  (mRAP),  mean  pulmonary 
artery  pressure  (mPAP),  cardiac  output  (CO)  and  total  pulmonary 
resistance (TPR). Among the noninvasive parameters studied (NYHA-FC, 
echocardiographic  parameters,  and  plasma  levels of  ANP,  BNP,  and 
catecholamines), only BNP was found to be an independent predictor of 
survival.  Additionally,  follow-up  measurements were  performed  at  3 
months  after  receiving  prostacyclin  therapy in  53  patients.  Changes  in 
plasma BNP levels correlated closely with changes in right ventricle end 
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diastolic pressure (RVEDP) and TPR.  BNP level at 3 months was found 
to  be  an  independent  predictor  of  mortality.  Two  studies assessed  the 
relationship between plasma norepinephrine and mortality in patients with 
IPAH, and it was not found to be an independent predictor of mortality in 
either. Zaloga et al. showed that elevations in plasma NE are coincident 
with  the  presence  of  noncardiogenic  pulmonary  hypertension  and  that 
acute  pharmacologic  reduction of  PVR does not  normalize  the loss  of 
pulmonary NE metabolism.
Increased  Uric  Acid  levels  are  believed  to  reflect  impaired 
oxidative metabolism,  since  tissue  hypoxia  depletes  adenosine 
triphosphate with  degradation  of  adenosine  nucleotides  to  compounds 
including UA. Since UA levels were shown to be associated with a poor 
prognosis in other disorders, investigators studied the association between 
serum UA  levels  and  prognosis  in  patients  with  IPAH. Nagaya  et  al 
studied 102 consecutive patients over a long period of time. Follow-up 
was concluded in June 1998, for a mean duration of follow-up of 31 ± 37 
months. Ninety-four percent of these patients were in NYHA-FC III or IV. 
Thirty  age-matched, healthy  volunteers  served  as  control  subjects.  UA 
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levels were significantly elevated in patients with IPAH as compared to 
control subjects for each gender group and the group as a whole. Serum 
UA levels increased in proportion to the severity of the functional class 
and  correlated  with  CO,  TPR,  and  MVO2.  Among the  noninvasive 
variables that were studied, serum UA levels were independently related 
to mortality. 
Lopes and colleagues30  reported that plasma von Willebrand factor 
antigen (vWF:Ag) is elevated in patients with IPAH, PAH associated with 
CHD,  and  other  assorted  disorders.  von  Willebrand  factor is  a  large 
multimeric glycoprotein that is synthesized and stored in endothelial cells. 
Therefore, it was hypothesized that levels of von Willebrand factor could 
be elevated in patients with PAH due to the associated abnormalities in 
endothelial cell function. Lopes and colleagues studied 11 patients with 
IPAH and  24  patients  with  PAH associated  with  CHD  over  a  1-year 
period. Twenty healthy volunteers served as the control group. Treatment 
included  anticoagulation,  antiplatelet  agents,  and  "anticongestive" 
measures.  vWF:Ag was elevated in patients with PAH as compared to 
control  subjects,  and  more  so  in  patients  with  IPAH than with  CHD. 
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Multivariate analysis showed that cause of PH and vWF:Ag levels were 
independently associated with survival. 
ROLE  OF  ECHOCARDIOGRAPHY  IN  PULMONARY 
HYPERTENSION 31,32
Pulmonary hypertension is easily recognized when the following M Mode 
and two dimensional echocardiographic features are present.
Diminished or absent ‘a’ (atrial) wave of the pulmonary wave.
Midsystolic closure or the notching of the pulmonary valve.
Enlarged chambers on the right side of the heart.
D-shaped left  ventricular cavity caused by a flattened ventricular 
septum.
However,  these  features  are  not  sensitive  for  pulmonary 
hypertension and are not predictive of right ventricle dysfunction. In a 
sense,  these  features  are  only  qualitative  and  do  not  provide  actual 
hemodynamic data.
Doppler echocardiography allows estimation of pulmonary artery 
pressures  and  PVR  by  measuring  tricuspid  regurgitation  velocity, 
pulmonary regurgitation velocity and right ventricle outflow tract (RVOT) 
36
flow velocity. 
The  American  College  of  Chest  Physicians  (ACCP)  Clinical 
Practice Guidelines emphasize the use of echocardiography in pulmonary 
arterial  hypertension (PAH) with much of the discussion involving the 
estimate of right ventricular systolic pressure (RVSP). As indicated in the 
The American College of Chest Physicians (ACCP) consensus guidelines, 
Doppler  echocardiography  is  the  “test  of  choice”  for  noninvasive 
measurement of pulmonary arterial pressure in patients in whom PAH is 
clinically suspected.
Less  widely  recognized—and  probably  underemphasized  in  the 
clinical practice guidelines—is the value of echocardiography in assessing 
end-organ manifestations of severe PAH. Right ventricular failure is the 
most  common cause of death in patients with PAH, and the results of 
several observational studies suggest that echocardiographic evaluation of 
right ventricular structure and function can provide important prognostic 
information33.  A Doppler-derived index of right ventricular myocardial 
performance (MPI) that represents the sum of isovolumetric contraction 
and relaxation times divided by the ejection time. This index of global 
right  ventricular  function  was  a  potent  and  independent  predictor  of 
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cardiac death and lung transplantation.
   Abnormalities in the Doppler flow velocity patterns of right ventricular 
ejection (due to increased right ventricular impedance) and left ventricular 
filling (due to abnormal ventricular interaction) are common findings in 
patients with severe PAH. In patients with PH, a short right ventricular 
acceleration time (<62 ms) and a ratio of early to late transmitral flow 
velocities (E/A) <1 were associated with reduced survival. 
Structural manifestations of right ventricular decompensation- right 
atrial  enlargement  (RAE)  and  paradoxical  displacement  of  the 
interventricular  septum  (IVS)  were  indicative  of  a  poor  prognosis  in 
patients  with  PAH  and  WHO  Class  III  or  Class  IV  symptoms.  A 
planimetered right atrial area in the apical four-chamber view exceeding 
20  cm2/m  and  a  value  >2  for  the  end-diastolic  eccentricity  index—a 
simple  measure  of  septal  displacement  measured  from the  parasternal 
short  axis  view—were  also  associated  with  a  poor  prognosis.  The 
presence  of  a  pericardial  effusion,  a  common finding  in  patients  with 
severe PAH that reflects an elevated right atrial pressure, was a powerful 
and independent predictor of mortality in PAH. In a series of 26 patients 
with  Idiopathic  PAH  receiving  conventional therapy,  Eysmann  and 
38
colleagues  studied 41  echocardiographic  variables  and  9  cardiac 
catheterization variables.  Although  several  factors  were  prognostic  on 
univariate analysis,  multivariate  life-table  analysis  of  noninvasive 
variables revealed the severity of pericardial effusion to be independently 
significant (p = 0.006). In an analysis of 79 of 81 Idiopathic PAH patients 
who participated in the randomized trial of IV epoprostenol, pericardial 
effusion was noted in 43 patients (54%). Patients with larger effusions 
generally  had  more  severely  impaired  exercise  performance.  Larger 
effusion  size  was  also  correlated  with  more  RA  dilatation,  greater 
displacement of the intraventricular septum during diastole, and more TR 
than  patients  with  no  or  trace  effusion.  Although there  was  not  an 
association between pericardial effusion and mortality at the end of the 
12-week study, effusion size was correlated with death (p = 0.02).
Therefore,  there  is  ample  evidence  to  support  a  comprehensive 
echocardiographic examination to assess the extent of target organ disease 
as an important component of the routine evaluation. The assessment by 
an  experienced  echocardiographer  of  the  degree  of  right  ventricular 
enlargement and dysfunction, utilizing simple measures—the presence of 
a pericardial  effusion,  an E/A ratio <1,  a right  ventricular  acceleration 
39
time <62 ms, a planimetered right atrial size >20 cm2/m, and a diastolic 
eccentricity index >2—or more complex parameters, such as the Doppler 
right  ventricular  index  or  the  Tei  Index,  can  complement  the  clinical 
evaluation in assessing prognosis and guiding therapy.
PROGNOSIS  IN  PULMONARY  HYPERTENSION  AS 
RECOMMENDED BY ACCP34
  In patients with Pulmonary hypertension, the following parameters, as 
assessed  at  baseline,  may  be  used  to  predict  a  worse  prognosis,  as 
suggested by The American College of Chest Physicians. 
Advanced  NYHA-FC.  Quality  of  evidence:  good;  net  benefit: 
substantial; strength of recommendation: A. 
Low 6MWT distance. Quality of evidence: good; net benefit: substantial; 
strength of recommendation: A. 
Presence  of  a  pericardial  effusion.  Quality  of  evidence: good; net 
benefit: substantial; strength of recommendation: A. 
Elevated  mRAP.  Quality  of  evidence:  fair;  net  benefit: substantial; 
strength of recommendation: A. 
Reduced CI. Quality of evidence: fair; net benefit: substantial; strength of 
recommendation: A. 
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Elevated  mPAP.  Quality  of  evidence:  fair;  net  benefit: intermediate; 
strength of recommendation: B. 
Elevated  Doppler Echocardiography  RV  (Tei)  index. Quality  of 
evidence: low; net benefit: intermediate; strength of recommendation: C. 
ECG findings of increased P-wave amplitude in lead II, qR pattern in lead 
V1, and World Health Organization criteria for RV hypertrophy. Quality of 
evidence: low; net benefit: intermediate; strength of recommendation: C. 
Elevated  BNP (>  180  pg/mL).  Quality  of  evidence:  low; net benefit: 
intermediate; strength of recommendation: C. 
Patients with IPAH treated with epoprostenol, persistence of NYHA-
FC III or IV status after at least 3 months of therapy may be used to 
predict  a  worse  prognosis.  Quality  of  evidence: fair;  net  benefit: 
substantial; strength of recommendation: A. 
Patients with scleroderma-associated PAH, reduced DLCO (< 45% of 
predicted)  may  be  used  to  predict  a  worse  prognosis. Quality  of 
evidence: low; net benefit: small/weak; strength of recommendation: C. 
In  pediatric  patients  with  IPAH, younger age at  diagnosis  may be 
used to predict a worse prognosis. Quality of evidence: low; net benefit: 
small/weak; strength of recommendation: C. 
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ECHOCARDIOGRAPHIC VIEWS OF THE RIGHT HEART35
Owing to the complexities in the geometry of the right heart, no 
single view is sufficient to visualize the right heart. The RV inflow is best 
seen with anterior and medial angulation of the transducer in the standard 
parasternal long axis view. The parasternal short axis view is useful for 
visualizing the base of the right heart, RA and IAS, RV outflow tract, 
pulmonary  valve  and  MPA and  its  branches.  Forward  and  regurgitant 
flow in pulmonary valve is seen in this view. Geometry and motion of the 
right  ventricle  is  seen  from  the  apical  four  chamber  view.  Doppler 
interrogation of tricuspid regurgitation is optimal in this view.
ECHOCARDIOGRAPHIC  INDICES  FOR  RIGHT  VENTRICLE 
DYSFUNCTION  –  A  PERSPECTIVE MYOCARDIAL 
PERFORMANCE INDEX – TEI  INDEX 36,37.
Studies have found several  novel  echocardiographic and Doppler 
measurements  of RV  function  to  be  risk  factors  for  heart  failure, 
independently of  traditional  risk  factors.  For  example,  Myocardial 
Performance Index (MPI) provided prognostic information beyond that of 
other measurements of cardiac function and traditional risk factors. 
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MPI has previously been shown to have prognostic value in patients 
with  dilated  cardiomyopathy,  amyloidosis,  coronary  heart  disease and 
symptomatic  heart  failure  as  well  as  in  the  general  population.  MPI 
provides prognostic information independently of other measurements of 
cardiac function and of traditional risk factors for heart failure. Therefore, 
MPI seem to be a clinically relevant measurement of global ventricular 
function and may  prove  to  be  a  valuable  tool  in assessing  the  risk  of 
developing right heart failure. 
Our knowledge of the natural history of heart failure indicates that 
both  asymptomatic  systolic  and  diastolic  dysfunction can  precede  the 
onset of overt heart failure. The utility of Myocardial Performance Index 
(MPI)  is  comparable  to  simultaneous  cardiac  catheterization 
measurements of right ventricular function as the MPI was found to reflect 
both systolic and diastolic function.
MPI mirrors both the depolarization and repolarization process. It 
seems like changes in cellular Ca2+ handling in the myocardium underlie 
much of the abnormal contractility and relaxation. In the failing heart, the 
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contraction and relaxation becomes slower explaining why MPI increases 
with deterioration of cardiac function. There is evidence that sub-clinical 
depolarization (and repolarization) defects to be early phenomena in the 
natural history of heart failure as noted above.
Myocardial performance Index is a unitless number reflecting the 
global performance of the ventricle. It was devised in the mid 1990’s (Tei 
et al). It is a simple index which incorporates both systolic and diastolic 
parameters and can be applied to either  left  or  right  ventricle.  Several 
studies have used this index as a prognostic indicator of left ventricular 
performance. The utility of MPI as an indicator of global RV performance 
is an area of interest in the recent past.
The ratio of isovolumic contraction time(IVCT) and ejection time 
(ET) was closely correlated to +dP/dt (reflecting systolic function) and the 
ratio of isovolumic relaxation time(IVRT) and ejection time was closely 
correlated to –dP/dt  (reflecting diastolic function). Therefore, MPI may 
be  considered  the  sum of  an  index reflecting  systolic function  and an 
index reflecting diastolic function. Thus, the superior predictive capacity 
of MPI could be explained by the fact that MPI reflects global  function, 
while other measurements are limited to reflect mainly either LV systolic 
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or diastolic function.
IVCT + IVRT
M P I  =         ET
According  to  the  above  equation,  systolic  dysfunction  is 
characterized by the prolongation of IVCT and decrease in ET. Whereas 
the  diastolic  dysfunction is  characterized  by  the  lengthening of  IVRT. 
Presence of both is indicated by an increase in MPI. The normal value of 
MPI of Left ventricle is 0.39 +/- 0.08.
MPI  is  helpful  in  risk  stratification  of  patients  with  pulmonary 
hypertension. For the right heart, the normal values are 0.28 +/- 0.04. An 
increase in the right ventricle MPI is a very sensitive and specific marker 
of pulmonary hypertension.  Thus MPI is of value in patients in whom 
tricuspid  regurgitation  is  either  not  present  or  cannot  be  quantified  to 
assess the severity of pulmonary hypertension.
Thus, MPI is a reliable and easily assessable measurement of global 
ventricular function, and as such,  suitable for  large-scale examinations. 
Nevertheless, further studies are needed in order to define the role of MPI 
in clinical practice. Clinically significant age- and gender-specific cut-off 
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points  need  to  be  defined;  furthermore  it  has  to  be determined  if 
pharmacological  and/or  non-pharmacological  interventions lower  MPI 
and whether lowering MPI modifies the risk associated with a high MPI.
ISOVOLUMETRIC  CONTRACTION  TIME  (IVCT)  & 
ISOVOLUMETRIC RELAXATION TIME (IVRT)
 Isovolumetric phase is the earliest phase of ventricular systole in 
which the ventricle contracts as a closed chamber without any change in 
the volume of the chamber. The isovolumic contraction time corresponds 
to when calcium enters the myoplasm from the sarcolemma.
Traditionally  IVRT  is  recorded  as  the  aortic  valve  closure  and 
mitral  valve  opening  time  in  the  Left  ventricle.  M  Mode 
echocardiography and pulsed wave Doppler were used for this purpose. 
Normal values approximates 65 +/- 20 msec. Isovolumic relaxation time 
reflects the removal of Ca2+ from the myoplasm by Ca2+-ATPases. 
Recently  continuous  wave  Doppler  echocardiography  has  been 
used  to  measure  IVRT.  The  Apical  5  chamber  view  is  used  for  this 
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purpose. Measurements made by this method is comparable to that made 
by invasive methods.  IVRT represents the earliest  phase of ventricular 
diastole. Abnormalities of this index has been described as a non invasive 
predictor of diastolic dysfunction. However, measurement of IVRT as the 
sole indicator of diastolic dysfunction is limited, since no information on 
ventricle filling is provided. 
RIGHT VENTRICLE SYSTOLIC FUNCTION
Right ventricle systolic function can be evaluated in several ways. 
It  is  affected  in  several  situations  like  Inferior  myocardial  infarction, 
pulmonary hypertension and arrhythmogenic right ventricular dysplasia. 
As with left ventricle, wall motion abnormality can be assessed in RV. 
Both right ventricle free wall and IVS should be evaluated. It provides a 
qualitative  assessment  of  RV  systolic  function.  A  more  quantitative 
approach involves the measurement of right ventricle volume and area at 
end diastole and end systole. RV area fractional shortening and Ejection 
fraction  can  be  calculated.  This  can  be  measured  using  the  M  mode 
echocardiography from the apical 4 chamber view.
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RIGHT  ATRIAL  AND  RIGHT  VENTRICLE  DIMENSIONS  IN 
ECHOCARDIOGRAPHY
For  several  reasons,  the  right  heart  anatomy  and  function  is  a 
complex one and has not been well studied. The right atrium is abnormal 
in  both  right  ventricle  volume  and  pressure  overload  states  and  RV 
failure. It is best visualised in echocardiography by the apical 4 chamber 
view or the sub costal view. RA dimensions can be measured in 2 ways. 
The  Linear  dimensions  in  2  different  axes  and planimetry  method are 
currently  used.  Another  qualitative  method of  assessing  RA size  is  to 
compare it with the Left atrium size. If the RA size is greater than the LA 
size, then RA enlargement is inferred.
Right  ventricle  dimension  assessment  is  very  difficult  for  the 
following  reasons.  Firstly,  the  complex  anatomical  shape  –  cresentic 
shape  of  the  cavity.  Secondly,  the  presence  of  irregular  endocardial 
surface. Thirdly, the complexity in its contraction mechanics, comparable 
to that of bellows. Lastly its location immediately behind the sternum also 
poses a problem in the evaluation of RV anatomy and function.
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RV  is  cresentic  in  its  minor  axis,  but  along  its  long  axis  it  is 
complex.  There  is  no  simple  geometric  three  dimensional  figure 
accurately  represents  this  chamber.  Contraction  is  also  complex  as 
mentioned  above.  Relatively  small  movements  produce  large  ejection 
volumes. Normally the RV is two thirds of the size of Left ventricle. 
 To measure the RV dimensions and volumes, both the area – length and 
Simpson’s rule has been employed. The area – length method measures: 
the estimate of short axis and a linear measure of length from the apical 4 
chamber view. Recently three dimensional echocardiography has resolved 
the  problem in  the  techniques  that  assumptions  about  the  shape  to  be 
made and also there was a lack of gold standard for comparison.
RIGHT  VENTRICULAR  ABNORMALITES  IN  PULMONARY 
HYPERTENSION38
The  role  of  RV is  to  deliver  oxygen deficient  blood to  the  gas 
exchange  membranes  of  the  pulmonary  circulation.  Under  normal 
circumstances,  there  is  little  impedance  with the resistance  only  about 
1/10th of  that  in  the  systemic  circulation.  Consequently  a  very  low 
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pressure  gradient  of  only  5mmHg is  required  to  pump blood into  the 
pulmonary  circulation.  In  addition  the  pressure  overload  on  the  right 
ventricle is prevented by the recruitment of newer vessels and distension 
of the compliant vessels in the pulmonary circulation.
Right ventricular performance is influenced by contractile state of 
the myocardium and extrinsic factors, including loading conditions, LV 
performance,  pericardial  constraint,  coronary perfusion,  function of the 
IVS and intrapericardial pressure. In the setting of pulmonary diseases, it 
is the alteration of loading conditions that is the greatest influence on the 
heart
Pathophysiologic response of the right ventricle or dysfunction of 
the  right  heart  can  be  due  to  pressure  overload,  volume overload and 
ischemia. Distinguishing between them is a key factor in ascertaining the 
etiology of the RV failure39.  The hemodynamic response to pulmonary 
vascular diseases causing pulmonary hypertension is a pressure overload 
state.
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Pressure overload of RV results in hypertrophy of both the RV free 
wall  and  the  IVS.  This  is  often  associated  with  increase  in  the 
trabeculations  of  the  right  ventricle.  The  parasternal  long axis  view is 
used  for  the  measurement  of  RV  free  wall  thickness.  RV  pressure 
overload also results in the flattening of the interventricular septum. It is 
the  result  of  abnormal  pressure  gradient  between  the  left  and  right 
ventricle.  A  characteristic  feature  of  the  RV  pressure  overload  is  the 
presence of the flattening of IVS through out the cardiac cycle in contrast 
from the RV volume overload where the flattening is a feature only in 
diastole40.
Weimann et al demonstrated the mechanism of paradoxical septal 
motion  in  patients  with right  ventricular  volume  overload  (RVVO)  41. 
Short axis cross-sectional, echocardiographic studies of the left ventricle 
(LV) and interventricular septum (IVS) were performed in  patients with 
paradoxical  septal  motion due to RVVO and in normal subjects.  Short 
axis study in normal subjects revealed the left ventricle to be a relatively 
circular structure during both diastole and systole. In patients with RVVO 
a change in LC diastolic shape was observed. This change in shape varied 
51
from a slight flattening of the LV and IVS during diastole to total reversal 
of  the  normal  direction  of septal  curvature  such  that  the  IVS became 
concave toward the RV and convex toward the LV. During systole the LV 
and IVS returned to their normal relatively circular  configuration.  This 
change in LV shape from diastole to systole resulted in net motion of the 
IVS  toward  the  right  ventricle (paradoxically).  This  study  therefore 
suggests that paradoxical septal motion in patients with right ventricular 
volume overload is a result of a change in the diastolic shape of the left 
ventricle.  In  patients  with  RV pressure  overload,  the  IVS paradoxical 
motion persisted through out the cardiac cycle.
Doppler  imaging  is  also  very  useful  in  RV  pressure  overload. 
Pulmonary  valve  flow  and  tricuspid  regurgitation  velocity  can  be 
measured42. The acceleration time is the time from onset to peak velocity 
which provides a rough estimate of increase in pulmonary artery pressure. 
The shorter the acceleration time, greater is the pulmonary artery pressure. 
Tricuspid regurgitation develops early in RV dysfunction, although severe 
regurgitation develops only in severe RV failure.
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In patients with severe pulmonary hypertension, RV is dilated when 
viewed from the apical 4 chamber view. A subjective criterion for RV 
dilatation is a right ventricular diastolic area equal to or greater than that 
of  the  left  ventricle.  RV  dilatation  is  also  observed  in  conditions 
producing right  ventricle  volume overload  conditions.  Such  conditions 
can be differentiated from those produced by RV pressure overload by a 
high eccentricity index that  persists  only in diastole and normalizes in 
systole.  Eccentricity index is  derived from the ratio of  two orthogonal 
minor axis measured from the short axis view. The normal value is 1.0. In 
conditions producing septal flattening, index is greater than 1.0.
    PULMONARY  ARTERY  SYSTOLIC  AND  DIASTOLIC 
PRESSURES42
A more  direct  measure  of  the  RVSP is  done  by  measuring  the 
tricuspid  regurgitation  jet  velocity.  Bernoulli  s  equation  is  used  to 
calculate the pressure gradient between RV and RA. 
Then RVSP is calculated by
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RVSP = 4 (TR velocity) 2 + P RA
Where TR velocity is the maximum velocity of the TR jet in m/sec and P RA is 
the pressure in RA.
With pulmonary hypertension, pulmonary artery diastolic pressure 
increases disproportionately creating a high pressure gradient and hence 
an  increased  end-diastolic  regurgitant  velocity.  Thus  in  pulmonary 
hypertension, pulmonary regurgitant velocity at end diastole is >2 m/sec.
LIMITATIONS OF DOPPLER ECHOCARDIOGRAPHY
Studies have demonstrated that the concordance between Doppler 
echocardiography  and  direct  measurement  via  RHC  worsens  as  the 
pressure  rises,  with  poorest  correlation  when  the  systolic  pulmonary 
pressure is over 100 mmHg. Doppler echo may also overestimate systolic 
PAP in a population comprising people with normal pressure.
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AIMS AND OBJECTIVES
To study the clinical profile of Idiopathic Pulmonary Hypertension 
patients.
To  study  the  utility  of  echocardiography  in  assessing  the  right 
ventricular function in patients with idiopathic pulmonary hypertension.
To measure the  Pulmonary artery systolic  pressure  in  Idiopathic 
Pulmonary hypertension using  Doppler Echocardiography.
To assess the structural abnormalities of the heart in patients with 
idiopathic pulmonary hypertension. 
To study the correlation between the clinical  grading of severity 
and echocardiographic grading of pulmonary hypertension.
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MATERIALS  AND METHODS
About  50 patients  who  got  admitted  to  the  Department  of 
Cardiology and Medicine in Govt Rajaji Hospital, Madurai between April 
2007 and May 2009 were chosen and studied. 
The type of study : analytical study
Selection criteria  and study population :
Inclusion criteria 
Fifty  patients (mean age 27.64±8.18 years, 44 females) who were 
admitted to our hospital and found to have Pulmonary Hypertension of 
obscure/unknown  etiology  underwent  a  complete  clinical  and 
echocardiographic  examination.  In  the  population  studied,  pulmonary 
hypertension  of  varying  severities  was  detected,  as  determined  by 
Doppler echocardiography.
Exclusion criteria 
Pediatric age group patients were not included in the study. Patients 
with Chronic Obstructive pulmonary Disease, cardiomyopathy, abnormal 
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left ventricular systolic function, valvular heart disease or congenital heart 
disease with Left to right shunt lesions were all excluded.
The  Institutional  ethical  committee  approved  the  study  and  all 
patients gave informed consent to undergo evaluation.
Methods :
All  the patients included in the study were subjected to detailed 
history  taking  and  complete  physical  examination.  They  were  also 
evaluated  for  the  etiology  for  pulmonary  hypertension  with  complete 
blood count (CBC), Renal function testing (RFT), Liver function testing 
(LFT),  Thyroid  function  testing  (TFT),  HIV  ELISA,  Anti  nuclear 
antibodies  (ANA),  Chest  X  Ray,  USG  abdomen,  High  resolution 
Computed Tomography of the Chest (HRCT) ,Pulmonary function testing 
(PFT). 
Clinical  grading  of  pulmonary  hypertension  severity  was  done 
according to the WHO functional classification.
All patients underwent a complete transthoracic echocardiographic 
study  including  two-dimensional,  M  Mode,  color  flow  and  spectral 
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Doppler using ALOKA SSD 4000 and PHILIPS IE-33 echocardiography 
machine. Continuous ECG monitoring of the patients was done during the 
procedure  with  the  patient  lying  in  standard  left  lateral  decubitus 
procedure. 
Standard  two-dimensional  echocardiographic  evaluation  of  right 
atrium (RA) and right ventricle (RV) size and function was performed. 
The right atrium and right ventricle were visualized by the apical  four 
chamber view (fig 6). RA size was evaluated using linear dimensions in 
the minor axis. Modified Simpson’s rule was employed for estimating RV 
area (fig 7).  In addition, right ventricular  end-diastolic (RV EDA) and 
end-systolic areas (RV ESA) were measured from the apical 4-chamber 
view to calculate right ventricular fractional area change (RV FAC). The 
main  pulmonary  artery  (MPA)  was  optimally  visualized  using  the 
parasternal  short  axis  views.  The  pulmonary  artery  size  was  measures 
below  the  pulmonic  valve  (fig  8).  M  mode  and  two  Dimensional 
echocardiography  were  used  to  document  presence  or  absence  of 
pericardial effusion (fig 9). The free fluid in the pericardial cavity was 
visualized as an echo-free space using the parasternal long axis and short 
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axis views. Isovolumetric contraction time (IVCT) (fig-10), isovolumetric 
relaxation time (IVRT) (fig-11) and ejection time (ET)  (fig-12)  were 
measured  across  the  tricuspid  valve  using  the  pulsed  wave  Doppler 
echocardiography during the tricuspid valve flow and subsequently right 
ventricular Myocardial Performance Index (MPI) or  the Tei  index was 
calculated using the standard formula  MPI  = IVCT+IVRT / ET.
Paradoxical  septal  motion was visualized  in  the  parasternal  long 
axis view (fig-13) and the ‘D’ sign was visualized by the parasternal short 
axis view as a flattening of the septum (fig 14). Pulmonary artery systolic 
pressures (PASP) were estimated using the approach of calculating the 
systolic pressure gradient between right ventricle and right atrium by the 
maximum velocity of the tricuspid regurgitant jet in continuous wave (Fig 
15&16). Doppler study using the modified Bernoulli equation and then 
adding to this value an estimated right atrial pressures based on both the 
size of the inferior vena cava and the change in caliber of this vessel with 
respiration. M mode echocardiography was used to study the ‘a’ wave of 
the pulmonary valve and midsystolic notching or closure of the valve (fig 
17).  Contrast  study  with  agitated  normal  saline  was  done  to  rule  out 
59
congenital or acquired shunt lesions (Fig 18&19). All the patients in our 
study had normal left ventricular systolic function and normal valves.
The  reference  limits  for  various  echocardiographic  indices  and 
parameters  used  in  this  study  were  adopted  from  the  standard 
echocardiographic  manuals.  The  diagnosis  of  pulmonary  hypertension 
and severity grading was done as follows:
Pulmonary Artery Systolic Pressure (PASP) measured  > 25 mmHg 
at rest was considered to be pulmonary hypertension.
Variable MILD MODERATE SEVERE
PASP mmHg 25-50 51-75 >75
The reference limits for the main pulmonary artery (MPA) diameter 
measured below the pulmonary valve:
Variable Reference 
range
Mildly
Dilated
Moderately 
dilated
Severely dilated
Pulmonary 
artery  size, 
cm
1.5 – 2.1 2.2- 2.5 2.6-2.9 ≥ 3.0
The reference  limits  for  Right  atrial  (RA) minor  axis  dimension 
measured in apical four chamber view are:
variable Reference 
range
Mildly 
enlarged
Moderately 
enlarged
Severely 
enlarged
RA minor axis 
dimension, cm
2.9 – 4.5 4.6 – 4.9 5.0 – 5.4 ≥ 5.5
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The reference limits used for the myocardial performance index for 
the right ventricle is 0.28 ± 0.04. 
The reference limits used for right ventricle end systolic area (RV 
ESA),  right  ventricle  end diastolic  area (RV EDA) and right  ventricle 
fractional area change (RV FAC) are as follows:
Variable Reference 
range
Mildly 
abnormal
Moderately 
abnormal
Severely 
abnormal
RV diastolic area, cm2 11 – 28 29 – 32 33 – 37 ≥38
RV systolic area, cm2 7.5 – 16 17 – 19 20 – 22 ≥23
RV fractional area change % 32 – 60 25 – 31 18 – 24 ≥17
M mode and 2 D echocardiography measurements of the echo-free 
space were used to grade the severity of pericardial effusion.
variable Mild Moderate large
Echo free space, cm <1 1 – 2 >2
Statistical Tools 
The  information  collected  regarding  all  the  selected  cases  were 
recorded in  a  Master  Chart.  Data  analysis  was  done  with  the  help  of 
computer using Epidemiological Information Package (EPI 2002).Using 
this software, frequencies, percentage; mean, standard deviation,  x2 and 
'p' values were calculated. A 'p' value less than 0.05 is taken to denote 
significant relationship.
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                                            RESULTS
The  results  of  clinical  evaluation  of  the  50  patients  are  shown 
below. The table 1 and Fig 20 show the age wise distribution of IPAH in 
our study. The mean of age of patients in our study is 27.64 ± 8.18 years.
Table 1
Age wise distribution of the disease
Age (In Years) Cases
No. %
Less than 20 6 12
20-24 18 36
25-29 6 12
30-34 8 16
35-39 6 12
40 & above 6 12
Total 50 100
Mean
S.D.
27.64 yrs
8.18 yrs
The number of patients belonging to each WHO functional class is 
shown in Table 2 and Fig 21.
Table 2
WHO Functional Classification
WHO Class Cases
No. %
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I - -
II 12 24
III 22 44
IV 16 32
Total 50 100
The table 3 below shows there is no statistical correlation between 
WHO functional class severity and age of the patients. 
Table 3
Relationship between WHO functional classification and Age
WHO Classification Age in years
Mean S.D.
II 24.5 7.12
III 30 9.27
IV 26.75 7.23
‘P’ 0.4748 (Not significant)
The  table  4  and  Fig  22  show  the  sex  wise  distribution  of  the 
disease.  Of the 50 patients,  44 (88%) were females and 6 (12%) were 
males.
Table 4
Sex Distribution
Sex Cases
No. %
Male 6 12
Female 44 88
Total 25 100
All the patients in  WHO functional class II (n=12) were females. 
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About 91% of the patients in class III (n=22) were females and 9% were 
males. Class IV (n=16) had 75% females and 25% males. The table 5 
shown below illustrates the findings.
Table 5
WHO Classification and Sex
WHO Classification Males Females
No. % No. %
II (6) - - 12 100
III(22) 2 9.1 20 90.9
IV (16) 4 25 12 75
The table 6 shows the common symptoms in our study population. 
Dyspnea on exertion is the most common symptom and was found in all 
our patients (100%). Fatigue is the second most common symptom in our 
patients (68%).
Table 6
Symptoms
Symptoms No. %
Dyspnea on exertion 50 100
Chest Pain 20 40
Giddiness 22 44
Syncope 4 8
Cough / Sputum 30 60
Palpitations 26 52
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Pedal edema 26 52
Hemoptysis 10 20
Fatigue 34 68
The correlation between the number of symptoms at  the time of 
presentation  and  WHO  functional  class  severity  was  statistically 
significant ( p = 0.0228).
Table 7
WHO Classification and number of symptoms present
WHO Classification Number of symptoms presentMean S.D.
II 5.0 1.41
III 3.82 1.25
IV 5.63 1.06
‘p’ 0.0228 ( Significant)
Among  the  50  patients,  46  patients  (92%)  showed  some 
abnormality in the complete blood count (CBC) and anemia was the most 
common abnormality and CBC was normal in the rest. 48 patients (96%) 
showed ECG abnormalities in the form of sinus tachycardia, right atrial 
enlargement  and right  ventricular  hypertrophy and right  axis  deviation 
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(fig- 23). 46 patients (92%) showed chest X ray evidence of pulmonary 
artery  dilatation  (fig-  24).  2  patients  (4%)  showed  evidence  of  apical 
fibrosis of right lung and 2 patients (4%) had a normal CXR.
The  renal  function  testing,  liver  function  testing  and  thyroid 
function testing revealed no abnormalities in the study population. HIV 
ELISA  and  anti  nuclear  antibodies  were  negative  in  all  the  patients 
included in our study. High resolution computed tomography of the chest 
showed no abnormalities of the pulmonary parenchyma and ruled out the 
possibility of pulmonary thromboembolic disease in our patients (fig -25). 
The  table  8  shows the echocardiograpic  parameters  measured to 
assess  right  heart  structural  changes  and functional  abnormalities. The 
mean size of the right atrium was 4.69 ± 1.22 cm. The right ventricle 
dimension as determined using Simpson’s rule rule had a mean value of 
28.93 ± 8.45 cm2 . The mean PASP in our patients was 92.52 ± 35.29 mm 
Hg. 10 patients (25%) had mild pulmonary hypertension, 4 patients (10%) 
had moderate pulmonary hypertension and 36 patients (65%) had severe 
pulmonary  hypertension.  The  mean  fractional  area  change  in  right 
ventricle is 18.48 ± 5.71 %. The mean value of MPI was 0.821 ± 0.205.
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Table 8
Echocardiographic measurements in our patients
Parameter Mean S.D.
RA cm 4.69 1.22
RV cm2 28.93 8.45
MPA cm 2.64 0.67
TRPG 82.52 35.29
PASP 92.52 35.29
RVESA 22.36 3.35
RVEDA 35.84 3.59
RVFAC 18.48 5.71
IVCT 82.08 14.14
IVRT 123.04 27.53
ET 256.7 41.2
MPI 0.821 0.205
Echocardiography  showed  all  the  patients  included  in  the  study 
showed features of absent ‘a’ wave and presence of mid systolic notch in 
the pulmonary valve. And 28 patients (56%) had pericardial effusion, 40 
patients (80%) had paradoxical motion or flattening of the interventricular 
septum.  Bubble  study  was  negative  in  all  the  patients  ruling  out  the 
possibility of abnormal left to right shunts.
The table 9 showed that the relationship between the RA size, RV 
size, Pulmonary artery size and the WHO functional class. Likewise the 
Table  10  shows  statistically  significant  relationship  between  WHO 
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functional class and echocardiographic indices for RV dysfunction like 
RV FAC and MPI.
Table 9
Relationship between WHO Functional Classification and structural 
abnormalities
Parameter
WHO Classification
II III IV
Mean S.D. Mean S.D. Mean S.D.
‘p’
RA cm 2.98 0.48 5.03 0.86 5.5 0.69 0.0008 (Significant)
RV cm2 15.05 2.79 32.34 3.29 34.67 1.54 0.0006 (Significant)
MPA cm 1.9 0.32 2.96 0.62 2.74 0.52 0.0041(Significant)
                                         Table 10
Relationship between WHO Classification and Echocardiographic 
Indices
Paramete
r
WHO Classification
II III IV
Mean S.D. Mean S.D. Mean S.D.
‘p’
TRPG 39.17 7.52 81.72 21.8 116.1
3
25.4
6
0.0002(Significant)
PASP 49.17 7.52 91.73 21.8 126.1
3
25.4
6
0.0002(Significant)
RVESA 17.5 1.52 23.45 2.38 24.5 1.2 0.0012(Significant)
RVEDA 31.67 2.07 37.09 3.45 37.25 2.12 0.0059(Significant)
RVFAC 26.67 2.34 16.18 2.6 15.5 4.72 0.0016(Significant)
MPI 0.641 0.08
4
0.783 0.16
0
1.049 0.08
5
0.0001( Significant
)
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                                 DISCUSSION
Demographic  studies  with  respect  to  IPAH  are  very  limited  in 
India. According to one report, there are 2 cases per million population in 
the west.  Exact incidence and prevalence rates could not be calculated 
from our study. There is a strong female preponderance in patients with 
IPAH. The male: female ratio in our study is approximately 1:7. The most 
common age group affected in our study population is in the 3rd and 4th 
decade in contrast to the reports from the west which have reported higher 
incidence  of  IPAH in  4th or  the  5th decade.  The  reason  for  the  early 
presentation in our study population is not known. The role of genes in 
determining the onset of disease and disease severity is still unsettled. 
Most patients in our study shared the clinical presentation. Exercise 
intolerance  in  the  exertional  dyspnea  and  fatigability  are  the  most 
common clinical manifestations in our study populations. 100 % of our 
patients has dyspnea as opposed to 60 % reported in another study. Other 
common  symptoms  include  chest  pain  (40%),  cough  (60%)  giddiness 
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(44%) and pedal edema (52%). The number of symptoms at the time of 
presentation has an effect  on the severity of the disease.  Patients  with 
more clinical symptoms belong to higher WHO functional class and has 
higher values of PASP.
Echocardiography  developed  over  the  last  three  decades  has 
become  an  extension  of  the  physical  examination  in  the  modern 
evaluation  of  a  patient  with  heart  disease.  The  review of  the  various 
studies shows this unique non invasive technique is useful in knowing the 
anatomical  and pathophysiological  alterations and in the hemodynamic 
evaluation of any case of disease leading to heart failure. 
The results of this study suggest that right ventricular dysfunction, 
represented by both structural and pathophysiological abnormalities occur 
in patients with pulmonary hypertension. Right ventricular abnormalities 
occurred  even  with  mild  elevations  of  pulmonary  artery  pressure.  In 
addition, they correlate well with markers of disease severity including 
pulmonary  hypertension  severity  index,  World  Health  Organization 
functional class. (p < 0.05)
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Among the structural abnormalities, the right ventricle dimension 
had a higher statistically significant correlation of WHO functional class 
severity (p = 0.0006) when compared to RA size (p = 0.0008) and MPA 
size (p = 0.0041).
The results of this study can be quite useful in the evaluation of 
chronic  pulmonary  hypertension  patients  given  the  well-known 
limitations  of  standard  echocardiography  in  the  assessment  of  right 
ventricular  size  and  function  due  to  the  complex  structure  and 
asymmetrical  shape  of  this  cardiac  chamber.  The  changes  in  right 
ventricular area obtained from the apical 4-chamber views were taken as 
indices of right ventricular size and global systolic function rather than 
ventricular  volumes  and  ejection  fraction,  which  appeared  to  be 
influenced  by  many  factors.  In  addition  RV  Myocardial  Performance 
Index,  a  well-recognized  measure  of  global  ventricular  systolic  and 
diastolic function that is independent on any geometric assumptions and 
heart rate was calculated from IVCT, IVRT and ET. 
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In our study, Myocardial Performance Index is found to have the 
highest correlation to WHO functional class severity (p = 0.0001). RV 
FAC  (p  =  0.0016)  and  PASP  (p  =  0.0002)  also  show  statistically 
significant correlation to WHO class. Thus MPI is the most sensitive and 
specific  marker  of  RV  dysfunction  in  patients  with  pulmonary 
hypertension.
The value of MPI has been widely applied in previous studies to 
quantify  regional  left  ventricular  myocardial  function  under  different 
clinical scenarios and all the available evidence suggests that it is quite 
useful  to  assess  left  ventricular  performance.  However,  despite  all  this 
knowledge on left ventricular mechanical activation, a few attempts have 
been made to quantify right ventricular dyssynchrony using these indices. 
In our study, we evaluated this index to assess RV function and use them 
as a marker of severity of pulmonary hypertension.
Presence  of  paradoxical  septal  motion  is  also  a  well-recognized 
marker  of  right  ventricular  deformation  by  either  pressure  or  volume 
loads. The variability in our measurements of RV size, morphology, and 
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functional  performance  in  patients  with  variable  degree  of  chronic 
pulmonary hypertension is probably due to the right ventricular geometric 
remodeling that occurs in these patients with pulmonary hypertension as 
described by Sukmawan et al.
Areas  of  further  work are  required  in  tissue  Doppler  imaging 
(TDI) which might be useful in the early identification of patients with 
sub clinical evidence of right ventricular dysfunction but further studies 
are  required.  In  addition,  the  long-term  effects  of  right  ventricular 
dysfunction  on  morbidity  and  mortality  as  well  as  whether  right 
ventricular resynchronization therapy that might correct right ventricular 
dysfunction  and  restore  right  ventricular  function  with  resultant 
improvement of markers of disease severity and functional capacity also 
require investigation.
There are patients whose resting hemodynamics are normal, but in 
whom marked elevations in pulmonary pressure occur with exercise. It 
has  been  presumed  that  this  represents  an  early  stage  of  pulmonary 
vascular disease. However, as patients may have a hypertensive response 
to  exercise  with respect  to  the systemic  vasculature,  a  similar  type  of 
response can occur in the pulmonary vasculature. Thus, whether exercise 
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induced  pulmonary  hypertension  represents  true  pulmonary  vascular 
disease  or  reduced  compliance  of  an  otherwise  normal  pulmonary 
circulation can be difficult to ascertain and this is one area where further 
research is yet to take off.
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LIMITATIONS OF THE STUDY
Several  important  limitations  of  these  studies  should  be 
acknowledged. The number of patients are relatively small in our study; 
However, even with this small number of patients we are able to reach our 
primary goal of identifying the presence of a statistically significant right 
ventricular  mechanical  dysfunction  in  patients  with  pulmonary 
hypertension. 
We have  evaluated  patients  with  the  available  investigations  for 
PAH and they are incomplete. An invasive pressure measurement is not 
used  in  this  study;  therefore,  assessments  of  right  ventricular  time-
pressure plots, dp/dt, and pulmonary vascular resistance are not available 
to compare with our echo data. 
Similarly, peak systolic pulmonary arterial pressures are estimated 
simply  based  on  tricuspid  regurgitation  measurements.  However,  this 
widely used Doppler-derived pressure estimation is well recognized and 
has  been  documented  to  have  a  good  correlation  with  simultaneously 
obtained  catheter-derived  measurements;  particularly  in  patients  with 
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elevated systolic pulmonary artery pressures. 
The  use  of  fractional  area  change  as  an  index  of  global  right 
ventricular  systolic  function  has  a  limitation  of  being  highly  afterload 
dependent  particularly  in  patients  with  pulmonary  hypertension.  This 
effect might be compounded by tricuspid regurgitation that by reducing 
systolic afterload augments right ventricular systolic function. 
Nonetheless,  the  very  consistent  theme that  has  emerged  is  that 
echocardiographic  evidence  of  right  ventricular  failure  is  an  ominous 
finding. Additional research to further define the role of echocardiography 
in assessing prognosis and guiding therapy in patients with PAH would be 
of value. 
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CONCLUSIONS
We conclude that  our study population also has a strong female 
preponderance and has a relatively earlier onset of the disease in the 3rd or 
the 4th decade.
The study also indicates that right ventricular abnormalities occurs 
in patients with chronic idiopathic pulmonary hypertension and is strongly 
correlated with  right atrial dimensions, right ventricular size and main 
pulmonary artery size, which are all increased with increasing severity in 
pulmonary hypertension. 
Other structural  abnormalities in pulmonary hypertension include 
presence of pericardial  effusion,  paradoxical  septal  motion of  IVS and 
pulmonary  valve  abnormalities  (absent  ‘a’  wave  and  presence  of  mid 
systolic notch or closure). 
In addition, right ventricular functional abnormalities including RV 
FAC and RV MPI are associated with disease severity and it correlates 
well  with  pulmonary  hypertension  severity  index,  World  Health 
Organization  class.  RV  FAC  decreases  with  increase  in  severity  of 
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pulmonary hypertension and MPI increases with increases with increase 
in PASP. 
Right  ventricular  dysfunction  is  clearly  evident  even  with  mild 
elevations  in  the  pulmonary  artery  systolic  pressure  and  Doppler 
echocardiography  is  the  test  of  choice  in  patients  suspected  to  have 
Idiopathic Pulmonary artery hypertension.
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APPENDIX I – PRO FORMA
EVALUATION OF PATIENTS WITH PULMONARY HYPERTENSION
NAME: AGE:     SEX:                OCCUPATION:
ADDRESS: IP/OP NO:    CD NO:
COMPLAINTS: WHO FUNCTIONAL CLASS - 
1. DYSPNEA 2. CHESTPAIN 3. GIDDINESS
4. SYNCOPE 5. COUGH/SPUTUM 6. 
PALPITATIONS
7. PEDAL EDEMA 8. HEMOPTYSIS 9. FATIGUE
OTHERS:
PAST HISTORY: 
SYSTEMIC HTN DM PUL TB BR ASTHMA
       RHD IHD DRUG INTAKE
PERSONAL HISTORY: SMOKING ALCOHOL EXPOSURE TO STD
MENSTRUAL / OBSTETRIC HISTORY:
FAMILY HISTORY:
EXAMINATION:
GENERAL EXAMINATION:
VITALS : PULSE BP RR TEMP
CVS: JVP
RS:
INVESTIGATIONS
Hb % TC DC    P     L        E        M    ESR HCt  
BLOOD SUGAR      UREA SERUM CREATININE
LIVER FUNCTION: THYROID FUNCTION:
HIV ELISA ANA USG ABDOMEN
CXR  : HRCT:
PULMONARY FUNCTION TESTING: PULSEOXIMETRY
ECG IN ALL LEADS:
ECHOCARDIOGRAM:
TTE:
VALVES  RA RV MPA AORTA
PERICARDIAL EFFUSION IVS PARADOXICAL MOVEMENT
TR PG PASP
LVEF
RV END SYST AREA RV END DIAS AREA
RV  FRACTIONAL AREA SHORTENING
RVIDd RVIDs ED PRPG
IVCT ICRT ET MPI =  IVCT+IVRT/ET
PULMONARY VALVE M – MODE
BUBBLE CONTRAST STUDY
TEE:
